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ABSTRACT
Objective: The objective of this study is to formulate a tablet that fits in the size range of mini-tablets using wax matrix forming substances, allows 
variation of drug dose and study of drug release kinetics of the dosage form.
Methods: The blends of drug with glyceryl monostearate, purified rice bran wax and carnauba wax that renders the waxes food grade, were prepared 
and evaluated for precompression characteristics. The blends were compressed into mini-tablets having desirable physical characteristics and 
were subjected to tests such as weight variation and friability. The tablets were subjected to drug dissolution test and the release parameters were 
mathematically treated for order and mechanism of drug release.
Results: The tablets complied with the pharmacopoeial standards of physical characteristics. The release was satisfactorily sustained (up to 10 hrs) 
by carnauba wax and rice bran wax, but not by glyceryl monostearate (only up to 4 hrs). The release followed a zero order with super Case II transport 
being the major mechanism of drug release.
Conclusion: Wax matrix formers were satisfactorily used for sustained drug release mini-tablets. The tablets had good physical characteristics with 
major mechanism of drug release being super Case II transport.
Keywords: Wax matrix, Sustained release, Mini-tablets, Montelukast sodium.
INTRODUCTION
The lipids we use in preparation of pharmaceutical formulations have 
their origin in the food stuff used. The lipids attract attention as they 
can help improve pharmaceutical product cycle and are cost-effective. 
They are used in various drug delivery systems intended to improve 
oral bioavailability and esthetics of the drug [1].
Mini-tablets are multiple unit dosage forms developed to retain 
advantages of formulations like pellets that include uniformity of 
drug release, less tendency of dose dumping, and greater patience 
compliance. However, mini-tablets score more advantages such as 
improved mechanical strength, more dose loading capacity, and 
uniformity of size and shape. Mini-tablets have a diameter in the range 
of 2 mm and can be presented filled in capsules like pellets or separately 
which serves an advantage of dose variation with the age and clinical 
condition of the patient [2].
Montelukast sodium, a leukotriene receptor antagonist, blocks the 
action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 
in lungs and bronchial tubes to decrease bronchoconstriction and 
inflammation. It is used in treatment of asthma and for symptomatic 
relief from seasonal allergies. Montelukast sodium is hygroscopic, 
optically active, white to off-white powder, freely soluble in ethanol, 
methanol, and water and practically insoluble in acetonitrile with a 
melting point 135.5°C and half-life 2.2-5.5 hrs [3].
The drug dispersed evenly in the lipid matrix diffuses when exposed 
to the dissolution medium. The drug on the surface dissolves forming 
pores for the dissolution medium to penetrate. Then the drug dissolves. 
Release follows square of time release kinetics. In case of a highly 
soluble drug such as Montelukast sodium, or large amount of soluble 
product in the matrix, the porosity of the matrix increases with 
dissolution time [4].
Erosion and/or partial solubilization may occur during the dissolution 
depending on the composition of the fatty compounds. In general, the 
erosion or solubilization of triglycerides is achieved in vivo by enzymes 
which hydrolyze the ester bonds of triglycerides. There are many 
enzymes called esterases, lipases which hydrolyze the ester bonds of 
triglycerides. These compounds can then be easily absorbed through 
the intestinal wall. However, the very long chains, C16-C22 (in case of 
glyceryl behenate, cetyl alcohol, and glyceryl monostearate) are hardly 
hydrolyzed, and hence, poor absorption through the intestinal wall [5].
The objective, therefore, is to formulate a tablet that fits in the size 
range of mini-tablets, allows variation of drug dose and study of drug 
release kinetics of the dosage form.
METHODS
Montelukast sodium was obtained as a gift sample from Zim 
Laboratories, Nagpur, pharmaceutical grade microcrystalline cellulose, 
glyceryl monostearate, magnesium stearate, Talc were obtained from 
HiMedia, Mumbai, polyethylene glycol (PEG) 4000, PEG 6000, carnauba 
wax and PEG 500 were obtained from Research Laboratories, Mumbai. 
Rice bran wax was procured from Maheshwari rice mills, Gondia. 
Solvents were obtained from SD Fine Chemicals and were distilled 
before use.
Purification of crude rice bran wax to get food grade rice bran 
wax [6]
The purification of rice bran wax involves two-step process 
commencing from the removal of residual oil with the help of solvent 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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n-hexane followed by isopropanol. The defatted wax is then bleached 
with sodium borohydride to yield a white compound which can be used 
further. About 100 g of crude rice bran wax was refluxed with about 1 L 
of n-hexane at about 50°C for 3 hrs. The mixture was cooled to about 
20°C and was filtered and dried. This dried wax, about 50 g was then 
refluxed with about 500 ml of isopropyl alcohol at about 80°C for 3 hrs 
and was then cooled to about 20°C and the residue was filtered. Most 
of the oil content is removed by n-hexane washing and remaining polar 
oils and lipids are washed in the isopropyl alcohol washing to yield a 
brownish wax which is harder to feel.
Bleaching of the defatted wax
The color is due to the presence of resinous matter which can be 
removed by bleaching. The defatted wax, about 50 g is refluxed with 
isopropyl alcohol at about 80°C in a two neck round bottomed flask 
fitted with a rubber cork. When the desired temperature is reached, 
the wax is bleached by drop wise addition of 10% solution of sodium 
borohydride. The process yields a separate layer of resinous matter, 
being more polar in nature, separates and the wax remains in the molten 
state. The mixture is filtered when hot to separate resinous matter and 
the white wax separates as solid crystals from the filtrate on cooling.
The rice bran wax was evaluated for its content and quality. By same 
procedure, carnauba wax was also purified and bleached.
Preparation of blends
Four different wax matrix formers were used namely PEG 4000, GMS, 
carnauba wax (purified and bleached), and rice bran wax (purified 
and bleached) in different batches and their influence on the tablet 
properties was compared. The wax matrix former was passed through a 
sieve no. 30 (ASTM). The drug and the other excipients were added after 
being passed through sieve no. 80 (ASTM) to the wax matrix former.
Evaluation of blends for compressed mini-tablets [7-12]
The blends were evaluated for their compressibility by measuring the 
angle of repose, Carr’s index and Hauser’s ratio.
Angle of repose
It is determined by allowing a powder to flow through a funnel and fall 
freely onto a surface. Further addition of powder is stopped as soon as 
the pile touches the tip of the funnel. A circle is drawn around the pile 
without disturbing it. The height and diameter of the resulting cone are 
measured. The same procedure is repeated three times and the average 
value is taken. Angle of repose is calculated using the following equation:
Tan θ=h/r
Where h = Height of the powder cone; r = Radius of the powder.
Bulk density
Unless otherwise specified, pass a quantity of material sufficient to 
complete the test through a 1.00 mm (no. 18 ASTM) screen to break up 
agglomerates that may have formed during storage. Into a dry 250 ml 
cylinder introduce, without compacting, approximately 100 g of the 
test sample (M) weighed with 0.1% accuracy. If it is not possible to use 
100 g, the amount of the test sample and the volume of the cylinder may 
be modified. Select a sample mass having an untapped apparent volume 
of 150-250 ml. A 100 ml cylinder is used for apparent volumes between 
50 and 100 ml. Fill the cylinder carefully. Carefully level the powder 
without compacting, if necessary, and read the unsettled apparent 






Accurately weighed quantity of powder is introduced into a measuring 
cylinder. Mechanically tap the cylinder containing the sample by 
raising the cylinder and allowing it to drop under its own weight 
using a suitable mechanical tapped density tester at a nominal rate 
of 300 drops/minutes. Tap the cylinder 500 times and measure the 
tapped volume (Va). Repeat the operation for an additional 750 tapings 
and again measure the tapped volume as (Vb).
If the difference between Va and Vb is <2%, Vb is the final tapped volume 
(Vf) If the difference is higher, repeat the tapings for an additional 
1250 times, and then, the tapped density can be calculated using the 
following formula (United States pharmacopoeia, 2004).
Tappeddensity  M
Vf
Where M = Weight of the sample taken; Vf = Final tapped volume.
Carr’s index and Hausner’s ratio [11]
The compressibility index of granules can be determined using 
Carr’s compressibility index, and can be determined by the following 
formula: The compressibility index of granules can be determined 
using Carr’s compressibility index, and can be determined by the 
following formula:













The compressibility index is evaluated for the interpretation of the flow 
of the granules. The relationship is presented in Table 1.
Size distribution of mixture was checked and the blends were 
compressed in Cemach make R&D press at 5 tons pressure.
Evaluation of mini-tablets [12]
The mini-tablets were evaluated for parameters such as weight 
variation, thickness, hardness, friability, disintegration time, dissolution 
time, taste and mouth feel.
a. Tablet thickness: Thickness was measured using vernier caliper.
b. Weight variation: Randomly selected 20 tablets from the lot were 
weighted individually to check for weight variation. Weight variation 
specification as per IP is shown in Table 2.
c. Friability: Preweighed tablets were placed in the Roche Friabilator 
for 100 revolutions. At the end of test tablets were dusted and 
Table 1: Interpretation of Carr’s index and Hausner’s ratio






32-37 Very poor 1.46-1.59
<40 Very very poor >1.60
Table 2: Weight variation test specifications as per IP
Average weight of tablet % deviation
80 mg or less ±10
>80 mg but <250 mg ±7.5
250 mg or more ±5
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reweighed; the loss in the weight of tablet is the measure of friability 
and is expressed in percentage as:
 % Friability = 1−(loss in weight/Initial weight)×100
 Limit-less than 1%
d. Hardness test: Tablet hardness was measured with Monsanto 
hardness tester. A tablet was placed in the hardness tester and load 
required to crush the tablet was measured. The force is measured 
in kg and the hardness of about 5-8 kg/cm2 was considered to be 
satisfactory for uncoated tablets.
e. Dissolution test: The dissolution method for oral disintegrating 
tablets was the same as that of conventional tablets. USP 2 paddle 
apparatus is most suitable and common choice for dissolution test 
of oral disintegrating tablets, where the paddle speed is 50 rpm is 
used.
f. Mathematical modeling of drug release: To determine the drug 
release rates, the results of the dissolution tests were fitted to 
the following equations. A regression analysis was used to obtain 
the release constant K and correlation coefficients r for each 
model. The correlation coefficients for the best statistical fit were 
used as the main criterion to evaluate the model.
i. Zero-order model [13]
C=(K0t)
 C = % drug release, K0 = Zero-order rate constant expressed in units 
of concentration/time (t).
ii. First-order model [13]
 log log
.
C C K tr = −0 1
2 303
 Cr = % remaining, C0 = Initial concentration of drug, K1 = First-order 
constant, t = Time.
iii. T. Higuchi model [14]
 If the drug is dispersed in homogenous matrix instead of being 
complexed or dissolved, the release kinetics are altered. Higuchi 
developed a mathematical model for analysis of such system: The 
release of dispersed drugs by diffusion from a stationary matrix 
such as ointment. The expression of drug released per unit area 
from slab takes form:
 Mt=(CsD(2A−Cs)t)1/2
 Where Mt is the amount of drug released per unit area at time t, 
D and Cs are the diffusion coefficient and solubility of the drug in 
the polymer, respectively, and A is the concentration of the drug 
initially present in the matrix. When A>>Cs, the equation reduces 
to:
 Mt=(2CsDAt)1/2
 This is known as Higuchi’s square root of t equation, which 
describes linear relationship between the amount of drug 
released and t1/2 provided D, A and Cs are constant. It was 
indicated that the model would only be suitable for systems 
where A exceeds Cs by a factor of three or more and it has been 
reported for polymer dispersions containing as less as 1% of 
drug. In this model, it is assumed that the solid rug dissolves 
from the surface layer and this layer becomes exhausted of drug 
particles.
iv. Korsmeyer and Peppas model [15-17]
Korsmeyer et al. derived a simple relationship, which described drug 






Where Mt/Ma is the fraction of drug released, t is the release time, 
k is a kinetic constant (with units of tn) incorporating structural and 
geometric characteristics of the release device and n is the release 
exponent indicative of the mechanism of release. This equation can 
be used to analyze the first 60% of a release curve where the release 
is linearly related to tn, regardless of geometric shape. Peppas (1985), 
Sahlin and Peppas (1989), have shown also that two competing release 
mechanisms, a Fickian diffusional release and a Case II relaxational 
release, are the limits of this phenomenon.
Fickian diffusional release occurs by the usual molecular diffusion 
of the drug due to a chemical potential gradient. Case II relaxational 
release is the drug transport mechanism associated with stresses and 
state-transition in hydrophilic glassy polymers, which swell in water or 
biological fluids. This term also includes polymer disentanglement and 
erosion. The value of the exponent for Case II transport mechanism is 
twice that of pure Fickian diffusional mechanism.
RESULTS
Rice bran wax and carnauba wax were evaluated for their 
physicochemical properties as per the methods specified in literature 
and the results are recorded as follows in Table 3.
Evaluation of granules
The formulation blends were considerably different in their physical 
and flow properties. The flow properties and packing properties of the 
blends show desirable characteristics for compression (Table 4).
Evaluation of mini-tablets
The mini-tablets were prepared by direct compression of blends using 
Cemach make R&D press. The thickness and hardness of the tablets was 
measured during compression regularly. The tablets were subjected to 
weight variation, friability, and assayed for drug content and the results 
are reported in Table 5.
Dissolution profile
The dissolution profile of mini-tablets is recorded in the following Table 6.
Drug release kinetic studies
Table 7 shows drug release kinetic studies.
DISCUSSION
According to the physicochemical properties of the waxes recorded 
in Table 3, it can be concluded that the purification process rendered 
the waxes food-grade [6]. The different blends were prepared as 
per amounts specified in Table 8. The blends were evaluated for 
compressibility and other properties as per the values and methods 
given in Tables 1, 2, 9 and 10. From the precompression parameters 
given in Tables 4 and 11, it is clear that the granules were suitable for 
compression. They possessed acceptable flow properties and hence 
were considered for compression. Carnauba wax and rice bran wax are 
Table 3: Physicochemical properties* of wax matrix substances








1 Melting pointa 84°C±0.2 81°C±0.2 56°C±0.2




4 Iodine valueb 10±0.1 8.1±0.3 3±0.2
*The values in the table designate average values of n=6 with±standard 
deviation values. aUSP29 NF24 general chapters <741>, bUSP29 NF24 general 
chapters <401>
Table 4: Flow property of formulations from angle of repose*







*The values in the table designate average values of n=6 with±standard 
deviation values
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from natural origin and showed good compressibility under moderate 
pressures. The tablet weight is adjusted compression, such that each 
tablet contains about 1 mg of active principle. The tablets formed had 
enough strength to withstand rigors of the postcompression tests and 
processes like packaging.
The dissolution profile of the formulations as shown in Table 6 endorsed 
the influence of nature of ingredients used as matrix formers. It can be 
easily inferred from Fig. 1 that the rate of drug dissolution is slower 
where carnauba wax and rice bran wax but the rate retardation is less 
may be due to small size of the tablets.
The release kinetics data when fitted as shown in Table 7, to different 
kinetic models, zero-order drug release was predominant as reflected 
form the regression values given for each equation.
Mechanism of drug release obtained by Korsmeyer–Peppas model was 
super Case II transport type. This is due to Fickian diffusion taking 
Table 5: Quality control tests* of mini-tablets
FC Hardness (kg/cm2) Thickness (mm) Friability%  Drug content (%) Weight variation test IP
F1 4.2±1.2 3.12±1.2 0.54±0.2 98.22±0.7 PASS
F2 4.1±0.3 3.23±1.7 0.62±0.8 99.33±1.2 PASS
F3 4.3±1.8 3.42±2.03 0.74±1.3 98.18±0.4 PASS
F4 4.8±1.3 3.12±0.4 0.58±2.1 98.35±0.2 PASS
F5 4.7±2.1 3.21±1.3 0.63±1.5 98.24±1.1 PASS
F6 4.8±2.3 3.23±0.2 0.71±1.2 98.25±1.3 PASS
*The values in the table designate average values with±standard deviation values
Table 6: Average cumulative drug release profiles of Montelukast formulations
Time (hr) Average % cumulative drug release time points of different batches (±SD of n=6)
F1 F2 F3 F4 F5 F6
1 9.72±(1.05) 5.17±(0.68) 29.52±(0.79) 24.28±(0.64) 9.42±(1.2) 5.06±(0.17)
2 19.27±(0.78) 15.05±(0.46) 56.41±(1.95) 51.97±(2.40) 20.98±(0.8) 14.73±(0.44)
3 38.44±(1.37) 31.35±(1.31) 74.86±(1.41) 74.24±(2.13) 40.51±(0.52) 30.64±(1.07)
4 61.02±(1.90) 51.96±(3.69) 99.19±(1.31) 95.34±(0.70) 60.25±(1.46) 50.47±(0.48)
6 80.92±(1.50) 70.55±(1.87) 80.11±(1.26) 70.60±(1.01)
8 99.10±(1.59) 90.01±(1.05) 99.11±(0.77) 89.89±(0.44)
10 98.89±(0.71) 99.26±(1.00)
SD: Standard deviation
Table 7: Drug release kinetics study
Kinetic model F1 F2 F3 F4 F5 F6
Zero order
K0 10.83 13.16 24.37 24.06 13.06 10.88
R2 0.973 0.980 0.993 0.997 0.983 0.975
First order
K1 −0.093 −0.180 −0.463 −0.313 −0.231 −0.191
R2 0.929 0.873 0.756 0.873 0.814 0.847
Higuchi plot
KH 37.47 35.51 48.16 46.98 37.3 35.57
R2 0.890 0.904 0.948 0.929 0.9 0.902
Korsmeyer–Peppas
KK 0.0008 0.013 0.019 0.004 0.014 0.0002
N 1.174 1.009 1.110 0.988 1.026 1.32
R2 0.979 0.952 0.970 0.996 0.949 0.969
Table 8: Formulation of mini‑tablets (content per two mini‑tablets)
Batch No. Montelukast 
sodium (mg)




Aerosil 200 (mg) Talc (mg)
F1 10 10 3 2 1
F2 10 20 - - 3 2 1
F3 10 - 10 3 2 1
F4 10 - 20 3 2 1
F5 10 10 3 2 1
F6 10 20 3 2 1
Table 9: Interpretation of angle of repose







>66 Very very poor
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Table 10: Interpretation of drug transport mechanism from release exponent
Release exponent Drug transport mechanism Rate dMt/dt as a function of time
0.5 Fickian diffusion t0.5
0.5<n <1.0 Anomalous (non-Fickian) 
transport
tn−1
n=1 Case II transport Zero-order  
(time independent) release
n>1.0 Super Case II transport tn−1
place along with the erosion of matrix with time. The erodible matrixes 
form channels for release of drug during course of dissolution studies. 
Hence, the drug release commences with diffusion as the predominant 
mechanism of drug release and then with the course of study, diffusion 
takes place along with the erosion of matrix that allows accelerated 
release of the drug.
CONCLUSION
Wax matrix formers, viz., glyceryl monostearate, purified rice bran wax, 
and carnauba wax were used in formulation of sustained release mini-
tablets. The matrix–formers allowed formulation of mini-tablets with 
desirable characteristics. The drug release studies showed that the 
release over a period of 10 hrs was achieved with carnauba wax and 
rice bran wax. Further delay in release was not achieved may be due to 
small size of the tablet.
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Table 11: Flow properties of formulation by Carr’s index and Hausner’s ratio
Formulations Bulk* density Tapped* density (g/cm3) Carr’s index# (%) Hausner’s ratio# Flowability@
F1 0.3946±0.47 0.4969±4.1 20.59 1.26 Passable
F2 0.371±0.43 0.4928±0.8 24.59 1.33 Passable
F3 0.3715±0.22 0.4925±1.8 24.57 1.33 Passable
F4 0.3986±2.03 0.5168±0.5 22.87 1.30 Passable
F5 0.3848±2.13 0.4917±1.1 21.74 1.28 Passable
F6 0.3647±2.14 0.4525±0.6 19.40 1.24 Passable
*The values in the table designate average values of n=6 with±standard deviation values, #values are calculated as on the basis of average values, @interpretation is 
based on average values of Carr’s index and Hausner’s ratio
Fig. 1: Average % cumulative drug release profiles of mini-tablets
